Abstract
The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 807-816 |
| Number of pages | 10 |
| Journal | Transplantation and Cellular Therapy |
| Volume | 27 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2021 |
Keywords
- CAR T-cell
- Cellular therapy
- Endpoint
- Immune profiling
- Minimal residual disease
- Multiple myeloma
ASJC Scopus subject areas
- Immunology and Allergy
- Molecular Medicine
- Hematology
- Cell Biology
- Transplantation
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Transplantation and Cellular Therapy, Vol. 27, No. 10, 10.2021, p. 807-816.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
AU - Holstein, Sarah A.
AU - Bahlis, Nizar
AU - Bergsagel, P. Leif
AU - Bhutani, Manisha
AU - Bolli, Niccolo
AU - Brownstein, Carrie
AU - Demolis, Pierre
AU - Foureau, David
AU - Gay, Francesca
AU - Ghobrial, Irene M.
AU - Gormley, Nicole
AU - Hillengass, Jens
AU - Kaiser, Martin
AU - Maus, Marcela V.
AU - Melenhorst, J. Joseph
AU - Merz, Maximilian
AU - Dwyer, Michael O.
AU - Paiva, Bruno
AU - Pasquini, Marcelo C.
AU - Shah, Nina
AU - Wong, Sandy W.
AU - Usmani, Saad Z.
AU - McCarthy, Philip L.
N1 - Funding Information: Financial disclosure: Supported by grant nos. U10HL069294 and U24HL138660 from the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The content is solely the responsibility of the authors and does not reflect the views or the official policy or position of the National Institutes of Health. This article reflects the views of the authors should not be construed to represent the FDA's views or policies. S.A.H. has served on advisory boards for Genentech, GlaxoSmithKline, Oncopeptides, Sanofi, Takeda; has served as a consultant for Celgene, Sorrento; has received research funding from Oncopeptides. N.B. has received honoraria from Janssen, Celgene, Amgen, Takeda, AbbVie, GlaxoSmithKline, Sanofi, Genentech, and Karyopharm; has served as a consultant/advisor for Janssen, Celgene, Amgen, Takeda, AbbVie, GlaxoSmithKline, Karyopharm, and Genentech. P.L.B. has served as a consultant for Bristol-Myers Squibb, Janssen, Amgen, and Novartis. M.B. has served on speaker bureaus for Amgen, Bristol-Myers Squibb, and Takeda; has served as a consultant for Sanofi Genzyme; has received research funding from Celgene, Bristol-Myers Squibb, Cerecor, Cellularity, Janssen, MedImmune, Takeda, and Prothena. N.B. has received honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, and Takeda; has served on advisory boards for Janssen and Celgene. C.B. is a full-time employee of Cellectis, Inc. F.G. has received honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, and Takeda; has served on advisory boards for Janssen, Celgene, Bristol-Myers Squibb, Amgen, Takeda, Adaptive Biotechnologies, Roche, Abbvie, and Oncopeptides. I.M.G. has served as a consultant or advisor for GlaxoSmithKline, Sanofi, Janssen, Takeda, Karyopharm, AbbVie, GNS, Cellectar, Adaptive, Bristol-Myers Squibb, and Oncopeptides. D.F. has received research funding from Celgene and TeneoBio. J.H. has received honoraria from Janssen; has served on advisory boards for Adaptive Biotechnologies, Amgen, AXXESS Network, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Oncotracker, Sanofi, and Skyline. M.K. has served as a consultant for Amgen, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Seattle Genetics, and Takeda; has received honoraria from Bristol-Myers Squibb/Celgene, Janssen, and Takeda; has received travel/educational support from Bristol-Myers Squibb/Celgene, Janssen, and Takeda; has received research support to institution from Bristol-Myers Squibb/Celgene. M.V.M. is an inventor on patents related to adoptive cell therapies held by Massachusetts General Hospital and University of Pennsylvnia (some licensed to Novartis); holds equity in Ichnos, TCR2, and Century Therapeutics; and has served as a consultant for Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, BMS, Cabaletta Bio (SAB), Cellectis (SAB), CRISPR therapeutics, In8bio (SAB), Innovakine, Intellia, GlaxoSmithKline, Kite Pharma, Micromedicine, Novartis, TCR2 (SAB), Tmunity, Torque, and WindMIL (SAB); is on the Board of Directors for Ichnos Science. J.J.M. has received research funding from IASO Biotherapeutics and Kite Pharma, a Gilead company; has served as speaker for Novartis and Johnson & Johnson; consults for Simcere of America, Shanghai Unicar Therapy, Janssen Research & Development, LLC, Poseida, Allogene, and IASO Biotherapeutics; is on the Medical and Scientific Advisory Board of IASO Biotherapeutics; holds patents related to CAR T cell manufacturing and biomarkers. M.O. has served as a consultant and advisor for Janssen, Abbvie, Amgen, Celgene, Adaptive Biotech, Glycomimetics, and Carrick Therapeutics; has received research support from Janssen, BMS, Abbvie, and ONK Therapeutics; has equity ownership in Carrick Therapeutics and ONK Therapeutics; is employed by ONK Therapeutics. M.C.P. has served as a consultant for Bristol-Myers Squibb and Amgen; has received research support from Kite, Novartis, and Bristol-Myers Squibb. N.S. has received research funding from Celgene/Bristol-Myers Squibb, Janssen, Bluebird Bio, Sutro biopharma, Teneobio, Poseida, and Nektar; has served as an advisor for GlaxoSmithKline, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides, and CSL Behring. S.W.W. has served as a consultant for Amgen; has served on advisory board for Sanofi; has received research support from Janssen, GlaxoSmithKline, Genentech, and Fortis. S.Z.U. has received research funding from Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Sanofi, SkylineDx, and Takeda; has received speaking fees from Amgen, Celgene, Janssen and Takeda. P.L.M. has served as a consultant for Bird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: SAH; wrote the manuscript. NB, MB, NB, CB, PD, DF, FG, IMG, NG, JH, MK, MVM, JJM, MM, MO, BP, MCP, NS, SWW, SZU, PLM; reviewed and edited the manuscript. Funding Information: Financial disclosure: Supported by grant nos. U10HL069294 and U24HL138660 from the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The content is solely the responsibility of the authors and does not reflect the views or the official policy or position of the National Institutes of Health. This article reflects the views of the authors should not be construed to represent the FDA's views or policies. S.A.H. has served on advisory boards for Genentech, GlaxoSmithKline, Oncopeptides, Sanofi, Takeda; has served as a consultant for Celgene, Sorrento; has received research funding from Oncopeptides. N.B. has received honoraria from Janssen, Celgene, Amgen, Takeda, AbbVie, GlaxoSmithKline, Sanofi, Genentech, and Karyopharm; has served as a consultant/advisor for Janssen, Celgene, Amgen, Takeda, AbbVie, GlaxoSmithKline, Karyopharm, and Genentech. P.L.B. has served as a consultant for Bristol-Myers Squibb, Janssen, Amgen, and Novartis. M.B. has served on speaker bureaus for Amgen, Bristol-Myers Squibb, and Takeda; has served as a consultant for Sanofi Genzyme; has received research funding from Celgene, Bristol-Myers Squibb, Cerecor, Cellularity, Janssen, MedImmune, Takeda, and Prothena. N.B. has received honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, and Takeda; has served on advisory boards for Janssen and Celgene. C.B. is a full-time employee of Cellectis, Inc. F.G. has received honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, and Takeda; has served on advisory boards for Janssen, Celgene, Bristol-Myers Squibb, Amgen, Takeda, Adaptive Biotechnologies, Roche, Abbvie, and Oncopeptides. I.M.G. has served as a consultant or advisor for GlaxoSmithKline, Sanofi, Janssen, Takeda, Karyopharm, AbbVie, GNS, Cellectar, Adaptive, Bristol-Myers Squibb, and Oncopeptides. D.F.. has received research funding from Celgene and TeneoBio. J.H. has received honoraria from Janssen; has served on advisory boards for Adaptive Biotechnologies, Amgen, AXXESS Network, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Oncotracker, Sanofi, and Skyline. M.K. has served as a consultant for Amgen, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Seattle Genetics, and Takeda; has received honoraria from Bristol-Myers Squibb/Celgene, Janssen, and Takeda; has received travel/educational support from Bristol-Myers Squibb/Celgene, Janssen, and Takeda; has received research support to institution from Bristol-Myers Squibb/Celgene. M.V.M. is an inventor on patents related to adoptive cell therapies held by Massachusetts General Hospital and University of Pennsylvnia (some licensed to Novartis); holds equity in Ichnos, TCR2, and Century Therapeutics; and has served as a consultant for Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, BMS, Cabaletta Bio (SAB), Cellectis (SAB), CRISPR therapeutics, In8bio (SAB), Innovakine, Intellia, GlaxoSmithKline, Kite Pharma, Micromedicine, Novartis, TCR2 (SAB), Tmunity, Torque, and WindMIL (SAB); is on the Board of Directors for Ichnos Science. J.J.M. has received research funding from IASO Biotherapeutics and Kite Pharma, a Gilead company; has served as speaker for Novartis and Johnson & Johnson; consults for Simcere of America, Shanghai Unicar Therapy, Janssen Research & Development, LLC, Poseida, Allogene, and IASO Biotherapeutics; is on the Medical and Scientific Advisory Board of IASO Biotherapeutics; holds patents related to CAR T cell manufacturing and biomarkers. M.O. has served as a consultant and advisor for Janssen, Abbvie, Amgen, Celgene, Adaptive Biotech, Glycomimetics, and Carrick Therapeutics; has received research support from Janssen, BMS, Abbvie, and ONK Therapeutics; has equity ownership in Carrick Therapeutics and ONK Therapeutics; is employed by ONK Therapeutics. M.C.P. has served as a consultant for Bristol-Myers Squibb and Amgen; has received research support from Kite, Novartis, and Bristol-Myers Squibb. N.S. has received research funding from Celgene/Bristol-Myers Squibb, Janssen, Bluebird Bio, Sutro biopharma, Teneobio, Poseida, and Nektar; has served as an advisor for GlaxoSmithKline, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, Oncopeptides, and CSL Behring. S.W.W. has served as a consultant for Amgen; has served on advisory board for Sanofi; has received research support from Janssen, GlaxoSmithKline, Genentech, and Fortis. S.Z.U. has received research funding from Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Sanofi, SkylineDx, and Takeda; has received speaking fees from Amgen, Celgene, Janssen and Takeda. P.L.M.. has served as a consultant for Bird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. Publisher Copyright: © 2021 The American Society for Transplantation and Cellular Therapy
PY - 2021/10
Y1 - 2021/10
N2 - The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.
AB - The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: (1) integrating minimal residual disease into clinical trial design and practice; (2) the molecular and immunobiology of disease evolution and progression in myeloma; (3) adaptation of next-generation sequencing, next-generation flow cytometry, and cytometry by time of flight techniques; and (4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field.
KW - CAR T-cell
KW - Cellular therapy
KW - Endpoint
KW - Immune profiling
KW - Minimal residual disease
KW - Multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=85117536576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117536576&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2021.05.027
DO - 10.1016/j.jtct.2021.05.027
M3 - Review article
C2 - 34107340
AN - SCOPUS:85117536576
SN - 2666-6367
VL - 27
SP - 807
EP - 816
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 10
ER -